PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Aug 9

PMID 32764981

Citations 7

Authors

Hongmei Luo

Ruixue Sun

Yuhuan Zheng

Jingcao Huang

Fangfang Wang

Dan Long

Yu Wu

Affiliations

Soon will be listed here.

Abstract

Purpose: Acute myeloid leukemia (AML) is associated with a poor overall prognosis. PIM family genes, including , and , are proto-oncogenes that are aberrantly overexpressed in different types of human cancers. In this study, we aimed to explore and clarify the function of in AML.

Patients And Methods: The expression of the three genes in AML was detected using the Gene Expression Omnibus. The expression of and PIM3 in patient samples and AML cell lines was measured using quantitative real-time polymerase chain reaction or Western blot analyses. The cellular behaviors of -overexpressing AML cell lines were detected using a CCK-8 assay, flow cytometry, Western blotting, immunofluorescence staining, and a cell migration assay. The interactions between PIM3 and phosphorylated CXCR4 (pCXCR4) were explored via immunoprecipitation.

Results: Higher expression was detected in primary AML cells than in healthy donor cells. Second, overexpression promoted AML cell proliferation and protected against spontaneous apoptosis by phosphorylating BAD (pBAD) at Ser112. Furthermore, overexpression might promote the migration of AML cells via CXCR4. -overexpressing AML cell lines exhibited increased CXCR4 phosphorylation at Ser339, and pCXCR4 interacted with PIM3.

Conclusion: Our findings suggest that PIM3 regulates the proliferation, survival, and chemotaxis of AML cell lines. Moreover, pCXCR4 might mediate the regulation of PIM3-induced chemotaxis. Therefore, the inhibition of expression may be a promising therapeutic target in AML.

Citing Articles

Kinase signalling adaptation supports dysfunctional mitochondria in disease.

Skalka G, Tsakovska M, Murphy D Front Mol Biosci. 2024; 11:1354682.

PMID: 38434478 PMC: 10906720. DOI: 10.3389/fmolb.2024.1354682.

Transient TKI-resistant CD44+pBAD+ blasts undergo intrinsic homeostatic adaptation to promote the survival of acute myeloid leukemia .

Xu Y, Baylink D, Chen C, Tan L, Xiao J, Park B Front Oncol. 2023; 13:1286863.

PMID: 38023123 PMC: 10664142. DOI: 10.3389/fonc.2023.1286863.

Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma.

Wang C, Chen Q, Luo H, Chen R World J Surg Oncol. 2023; 21(1):76.

PMID: 36871027 PMC: 9985240. DOI: 10.1186/s12957-023-02947-5.

Targeting Pim kinases in hematological cancers: molecular and clinical review.

Bellon M, Nicot C Mol Cancer. 2023; 22(1):18.

PMID: 36694243 PMC: 9875428. DOI: 10.1186/s12943-023-01721-1.

Current methods for studying metastatic potential of tumor cells.

Bouchalova P, Bouchal P Cancer Cell Int. 2022; 22(1):394.

PMID: 36494720 PMC: 9733110. DOI: 10.1186/s12935-022-02801-w.

References

Aho T, Sandholm J, Peltola K, Mankonen H, Lilly M, Koskinen P . Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004; 571(1-3):43-9. DOI: 10.1016/j.febslet.2004.06.050. View

Li Y, Popivanova B, Nagai Y, Ishikura H, Fujii C, Mukaida N . Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res. 2006; 66(13):6741-7. DOI: 10.1158/0008-5472.CAN-05-4272. View

Holder S, Abdulkadir S . PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance. Curr Cancer Drug Targets. 2013; 14(2):105-14. DOI: 10.2174/1568009613666131126113854. View

Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A . The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A. 1989; 86(22):8857-61. PMC: 298389. DOI: 10.1073/pnas.86.22.8857. View

de Bock C, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O . HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018; 8(5):616-631. DOI: 10.1158/2159-8290.CD-17-0583. View

Grundler R, Brault L, Gasser C, Bullock A, Dechow T, Woetzel S . Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med. 2009; 206(9):1957-70. PMC: 2737164. DOI: 10.1084/jem.20082074. View

Goldberg L, Tijssen M, Birger Y, Hannah R, Kinston S, Schutte J . Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood. 2013; 122(15):2694-703. PMC: 3795462. DOI: 10.1182/blood-2013-01-477133. View

Hiasa M, Teramachi J, Oda A, Amachi R, Harada T, Nakamura S . Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia. 2014; 29(1):207-17. DOI: 10.1038/leu.2014.147. View

Braso-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E . PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016; 22(11):1303-1313. PMC: 5552044. DOI: 10.1038/nm.4198. View

10.

Blanco-Aparicio C, Carnero A . Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol. 2012; 85(5):629-643. DOI: 10.1016/j.bcp.2012.09.018. View

11.

Mondello P, Cuzzocrea S, Mian M . Pim kinases in hematological malignancies: where are we now and where are we going?. J Hematol Oncol. 2014; 7:95. PMC: 4266197. DOI: 10.1186/s13045-014-0095-z. View

12.

Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E . High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002; 32(1):153-9. DOI: 10.1038/ng950. View

13.

Kuo H, Ezell S, Hsieh S, Schweighofer K, Cheung L, Wu S . The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Am J Cancer Res. 2016; 6(11):2489-2501. PMC: 5126268. View

14.

Zhang P, Pei X, Li K, Jin L, Wang F, Wu J . Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer. 2019; 18(1):179. PMC: 6900862. DOI: 10.1186/s12943-019-1111-2. View

15.

Mukaida N, Wang Y, Li Y . Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci. 2011; 102(8):1437-42. DOI: 10.1111/j.1349-7006.2011.01966.x. View

16.

Alvarado Y, Giles F, Swords R . The PIM kinases in hematological cancers. Expert Rev Hematol. 2012; 5(1):81-96. DOI: 10.1586/ehm.11.69. View

17.

Zhou Z, Tian Z, Yuan Z . [Expression and Significance of Pim-3 Gene in Acute Myeloid Leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016; 24(2):316-20. DOI: 10.7534/j.issn.1009-2137.2016.02.002. View

18.

Asri A, Sabour J, Atashi A, Soleimani M . Homing in hematopoietic stem cells: focus on regulatory role of CXCR7 on SDF1a/CXCR4 axis. EXCLI J. 2016; 15:134-43. PMC: 4827072. DOI: 10.17179/excli2014-585. View

19.

Boac B, Abbasi F, Ismail-Khan R, Xiong Y, Siddique A, Park H . Expression of the BAD pathway is a marker of triple-negative status and poor outcome. Sci Rep. 2019; 9(1):17496. PMC: 6877530. DOI: 10.1038/s41598-019-53695-0. View

20.

Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J . PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010; 95(6):1004-15. PMC: 2878801. DOI: 10.3324/haematol.2009.017079. View